New Issue: Orbital Catastrophe Ahead? Read Now

Divining the Right Drug

A new device may take the guesswork out of prescribing an antidepressant that works

Join Our Community of Science Lovers!

Imagine suffering from the crushing weight of major depression, then finally getting diagnosed and starting treatment with a drug—only to realize after two months that the medication, despite its unpleasant side effects, is not alleviating your depression. Unfortunately, this experience is far from rare: more than two thirds of patients with depression have no luck with the first medication they are prescribed and must also endure the withdrawal effects that come with discontinuing a drug before trying a new one. Finding the right treatment can prove a lengthy, painful process of trial and error. A new technology, however, may bypass this ordeal by gauging very early in a treatment regimen how well a drug is working based on the patient’s brain waves.

The technology, called quantitative electro­enceph­alography (QEEG), measures a person’s brain-wave pattern with EEG and then compares it with a database of normal samples to detect abnormal function. In a study published in the September 2009 issue of the journal Psychiatry Research, scientists used QEEG to record brain activity in subjects with major depressive disorder before they began treatment, after one week on an antidepressant and after eight weeks on the drug—the period it takes such drugs to achieve full effect. Changes in the QEEG readout after just one week of medication predicted 74 percent of the time whether patients would experience either a recovery or a remission of symptoms by the end of eight weeks.

“There appear to be changes in brain electrical activity that occur as early as a week, when the patient isn’t feeling any different,” says Andrew Leuchter, a psychiatrist at the University of California, Los Angeles, and lead author of the study. The result “proved [this QEEG-based technique] was in the range of something that could be useful to patients,” he states.


On supporting science journalism

If you're enjoying this article, consider supporting our award-winning journalism by subscribing. By purchasing a subscription you are helping to ensure the future of impactful stories about the discoveries and ideas shaping our world today.


Further research is needed to verify the technique’s promise, so Leuchter estimates it may be several years before QEEG can be used in the clinic. Still, the technique presents a much needed way to judge a drug’s efficacy, says psychologist D. Corydon Hammond, a pro­fessor at the University of Utah School of Medicine, who was not involved in the study. “Psychiatry has been in drastic need of more scientific and objective methods for medication selection for years,” Hammond says. He praised the study as “important” and added, “Many more like it are needed and with other conditions besides depression.”

Allison Bond is a resident in internal medicine at Massachusetts General Hospital in Boston. Her writing about science and medicine has appeared in a variety of publications, including The New York Times, Scientific American, Scientific American MIND, Discover magazine, and Reuters Health.

More by Allison Bond
SA Mind Vol 21 Issue 1This article was published with the title “Divining the Right Drug” in SA Mind Vol. 21 No. 1 (), p. 9
doi:10.1038/scientificamericanmind0310-9a

Subscribe to Support Independent Journalism

Great science journalism requires human expertise, time, effort and creativity. And it costs money. That’s why I and the journalists here at Scientific American hope you’ll join our community.

When you subscribe, you are supporting staff and freelance journalists who are passionate about telling science stories that are true, important and compelling. Our editors and reporters are often experts in their fields, which means they understand the nuances of big discoveries and can untangle the breakthroughs from the hype. With a subscription, you are also supporting rigorous fact-checking to ensure the words we publish are precise and accurate. And you’re supporting original illustrations, graphics and photos that bring you closer to an advanced laboratory, an ice sheet in Antarctica or a space mission in orbit. You’re helping us craft other types of high-quality journalism as well: Our newsletters are carefully written, edited and curated by staffers you have or will come to know and love. Our Science Quickly podcast is based on original reporting, collaboration with editors and scientists and exacting production.

Subscriptions keep this engine running so we can continue to deliver thoughtful, rigorous and independent science journalism to you. In an era of viral misinformation, this work is crucial. If you value what we do, I hope you’ll consider joining us as a subscriber

Thank you,

Jeanna Bryner, Editor in Chief, Scientific American

Subscribe